Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
76-90 of 298
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH
Kathleen Moore, MD, MS
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
Advancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
CME/CEAdvancing Clinical Expertise in CELMoDs: Transforming Multiple Myeloma Treatment
Joshua Richter, MD
Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
MinuteCE®Quick Case: Strategizing Treatment Selection in HER2-/PD-L1+ Gastric Cancer
James M. Cleary, MD, PhD
Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
MinuteCE®Guideline Recommendations in First-Line Treatment of HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
James M. Cleary, MD, PhD
- advertisement
Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
MinuteCE®Pivotal Data in Anti-PD-1 Strategies for HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
James M. Cleary, MD, PhD
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
MinuteCE®Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From ESMO 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
MinuteCE®Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC
Lauren A. Byers, MD
Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
MinuteCE®Clinical Implications of Emerging Data on B7-H3–directed ADCs in the Future of ES-SCLC
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
MinuteCE®Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
- advertisement
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Luis Paz-Ares, MD, PhD
Lauren A. Byers, MD
Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
MinuteCE®Clinical Criteria and Imaging Strategies for B7-H3–Directed ADCs in ES-SCLC
Luis Paz-Ares, MD, PhD
